Bone–cartilage interface crosstalk in osteoarthritis: potential pathways and future therapeutic strategies  by Yuan, X.L. et al.
Osteoarthritis and Cartilage 22 (2014) 1077e1089ReviewBoneecartilage interface crosstalk in osteoarthritis: potential
pathways and future therapeutic strategies
X.L. Yuan, H.Y. Meng, Y.C. Wang, J. Peng, Q.Y. Guo, A.Y. Wang*, S.B. Lu
Institute of Orthopedics, Chinese PLA General Hospital, Fuxing 28# Road, Beijing, Chinaa r t i c l e i n f o
Article history:
Received 4 February 2014
Accepted 28 May 2014
Keywords:
Osteoarthritis
Boneecartilage interface
Subchondral bone
Crosstalk
Molecular interaction* Address correspondence and reprint requests to
thopedics, Chinese PLA General Hospital, Fuxing 28#
E-mail address: aiyuanwang301@126.com (A.Y. W
http://dx.doi.org/10.1016/j.joca.2014.05.023
1063-4584/© 2014 Osteoarthritis Research Society Ins u m m a r y
Currently, osteoarthritis (OA) is considered a disease of the entire joint, which is not simply a process of
wear and tear but rather abnormal remodelling and joint failure of an organ. The boneecartilage
interface is therefore a functioning synergistic unit, with a close physical association between sub-
chondral bone and cartilage suggesting the existence of biochemical and molecular crosstalk across the
OA interface. The crosstalk at the boneecartilage interface may be elevated in OA in vivo and in vitro.
Increased vascularisation and formation of microcracks associated with abnormal bone remodelling in
joints during OA facilitate molecular transport from cartilage to bone and vice versa. Recent reports
suggest that several critical signalling pathways and biological factors are key regulators and activate
cellular and molecular processes in crosstalk among joint compartments. Therapeutic interventions
including angiogenesis inhibitors, agonists/antagonists of molecules and drugs targeting bone remod-
elling are potential candidates for this interaction. This review summarised the premise for the presence
of crosstalk in boneecartilage interface as well as the current knowledge of the major signalling path-
ways and molecular interactions that regulate OA progression. A better understanding of crosstalk in
boneecartilage interface may lead to development of more effective strategies for treating OA patients.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) represents a group of degenerative joint
diseases characterised by degeneration of articular cartilage, sy-
novial inﬂammation and changes in periarticular and subchondral
bone. OA is considered a disease of the entire joint, involving all
joint tissues1. Cartilage, synovium, bone and bone marrow as well
as menisci, ligaments, muscles and neural tissues are involved in
the complex initiation and progression of the disease. OA is not
simply a process of wear and tear but rather an abnormal remod-
elling and joint failure2.
The boneecartilage interface contains the region between the
deep layers of articular cartilage and the underlying subchondral
bone. This region comprises the tidemark, calciﬁed cartilage layer
and subchondral bone plate. The boneecartilage interface is
therefore a complex functional unit and biocomposite at the centre
of joint function and disease in which the individual components
interact cooperatively and synergistically3. Biomechanical and
biological processes result in alterations in the composition,: A.Y. Wang, Institute of Or-
Road, Beijing, China.
ang).
ternational. Published by Elsevier Lstructure and functional properties of this unit. Given the intimate
contact between bone and cartilage, alterations of either tissue will
modulate the properties and function of the other components, as
shown in Fig. 14.
The close physical association between subchondral bone and
cartilage suggests the possibility of biochemical and molecular
crosstalk across the interface in healthy and osteoarthritic joints.
The perspective that calciﬁed cartilage and bone is an insur-
mountable and impermeable barrier to soluble molecules and
functional interaction has changed, and new evidence indicates the
important role played by the boneecartilage biomechanical unit in
the development and progression of OA. Increased vascular
communication channels, ﬁssures and microcracks through the
complex and the irregular anatomy of the boneecartilage junc-
tiondwhich could act as a transport conduitdfacilitate molecular
transport, suggesting that crosstalk in molecular interactions exists
between cartilage and the subchondral bone. Mediators produced
from both tissues may pass from one zone to another, affecting the
homeostasis of neighbouring tissues. Collectively, this evidence
indicates that crosstalk in the boneecartilage interface is a holistic
system, highlighting the involvement of multiple factors and their
contribution to OA mechanisms. A comprehensive approach could
determine the cascade of events and integrate molecular and
cellular data regarding the progression of OA.td. All rights reserved.
Fig. 1. Differences between normal and osteoarthritic joints. OA is considered to involve all joint tissues. The boneecartilage interface is at the centre of joint function and
disease.
X.L. Yuan et al. / Osteoarthritis and Cartilage 22 (2014) 1077e10891078In this review, we summarise the biological and pathological
evidence for the presence of crosstalk in the boneecartilage
interface. In particular, we discussed the critical signalling path-
ways and molecular interactions in vivo and in vitro. We also
focused on therapeutic interventions that modulate crosstalk and
improve OA outcomes.
The basis for elevated crosstalk in the osteoarthritic
boneecartilage interface
Articular cartilage and subchondral bone alterations
Osteochondral changes include loss of cartilage, increased sub-
chondral bone thickness, decreased subchondral trabecular bone
mass, new osteophyte formation at the marginal joint, gradual
development of bone cysts and bone marrow lesions (BML). Other
changes include tidemark duplication, thickening of the calciﬁed
cartilage layer, cracks extending through the cartilage down to the
subchondral bone, and the development of chondrocyte clones,
connective vascular structures and blood vessels5 (Fig. 2).
During the progressive stages of OA, degeneration in the ma-
terial properties and structural integrity of articular cartilage can be
caused by associated changes in the molecular composition of the
matrix. Articular chondrocytes increase the synthesis of matrix
molecules but also contribute to their own destruction by synthe-
sising proinﬂammatory cytokines, including interleukin (IL)1, and
tissue-destructive enzymes such as matrix metalloproteinases(MMPs) and metalloproteinases with thrombospondin motifs
(ADAMTS)6. Extensive cellular changes are accompanied by
increased expression of molecules related to chondrocyte hyper-
trophy and terminal differentiation, such as vascular endothelial
growth factor (VEGF), runt-related transcription factor 2 (RUNX2)
and MMP137. The normally quiescent chondrocytes undergo a
phenotypic shift to become activated cells. Chondrocyte prolifera-
tion, cluster formation and increased production of matrix proteins
and enzymes that degrade speciﬁc ECM proteins are followed by
ampliﬁed catabolic activity leading to matrix remodelling and loss
of the cartilaginous structure, inappropriate hypertrophy-like
maturation and cartilage calciﬁcation, ﬁssures and microcracks.
As a result, the cartilage surface becomes rough, accompanied by
ﬁbrillation and a reduction in thickness8,9.
Subchondral bone remodelling is the initial step in abnormal
mechanical loading and involves bone matrix formation and
degradation by osteoblasts and osteoclasts. Bone turnover is likely
to play a pivotal role in the pathogenesis of OA10. OA is associated
with early bone loss due to increased bone remodelling, followed
by slow turnover leading to densiﬁcation of the subchondral plate
and complete loss of cartilage11. Elevated bone remodelling and its
associated stimulated vascularity are reportedly indispensable for
the progression of OA11.
In the early stages ofOA, bone remodelling and subchondral bone
loss are elevated. An increased number of osteoclasts with reduced
trabecular thickness and increased bone loss as well as lower
modulus were detected. The increased rates of bone remodelling
Fig. 2. The basis of crosstalk in early and late stages of OA. In the early stages of OA, mechanical overload promotes subchondral bone resorption and cartilage degradation.
Neoangiogenesis and neurogenesis pass the tidemark into the cartilage. Microcracks and BMLs occur secondary to abnormal mechanical load. In the late stages of OA, cartilage
matrix loss and chondrocyte hypertrophy, followed by the appearance of ﬁssures and the cutting of channels, extend down the subchondral plate. In contrast, the thickened calciﬁed
cartilage contains apoptotic chondrocytes and cysts. Subchondral bone sclerosis is related to an increase in osteoblastic bone formation.
X.L. Yuan et al. / Osteoarthritis and Cartilage 22 (2014) 1077e1089 1079may cause alterations in joint shape and load transmission that
predispose toprogressive cartilage loss.Microstructural impairment
of subchondral bone was associated with increased remodelling of
aggravated cartilage damage in OA rabbits with osteoporosis12.
Thinning and increased porosity of the subchondral bone platewere
signiﬁcantly related to cartilage damage13. In contrast, subchondral
bone becomes sclerotic in late OA. Bone formation and osteoblastic
activity dominate in this phase a higher bone density and volume14.
Although late-stageOA is associatedwith thickening of subchondral
bone, the stiffness of subchondral bone is low, accompanied by
decreased mineralisation15.
Bone attrition, deﬁned as depression or ﬂattening of the sub-
chondral bony surface unrelated to gross fracture16, is the decrease
or loss of bone height and contour that accompanies the osteoar-
thritic changes in bone. These changes likely represent remodelling
of subchondral bonewhich can occur in the early andmiddle stages
of OA. Subchondral bone attrition is also associated with the
severity of cartilage loss in adjacent regions, and areas of
BML detected by MRI, indicating an increased load on the bone-
ecartilage biomechanical unit17,18.
BMLs are indicators of OA progression and are considered an
important risk factor for structural deterioration19. These changes
are consistent with localised activation of bone repair processes
accompanying bone remodelling to increase the mechanical load20.
The localisation of BMLs was associated with areas of severe
cartilage loss in the overlying articular surface and revealed fat
necrosis and localised marrow ﬁbrosis associated with micro-
fractures of the trabecular bone21. Bone marrow oedema and sub-
chondral cysts are useful for assessing OA progression byMRI. BMLs
appear sclerotic due to increased bone volume fraction and
decreased tissue mineral density as well as increased trabecular
thickness. These changes may render this area mechanically
compromised and thus susceptible to attrition22.
Osteochondral angiogenesis and nerve growth
Angiogenesis and sensory nerve growth are closely integrated
processes that are potentially linked to the elevated crosstalk in OA.In OA, increased osteoclast activity causes channels to extend from
the subchondral bone and ultimately pass across the tidemark into
the articular cartilage. Channel formation in regions of vascular
invasion is associated with localised subchondral bone marrow
replacement by VEGF-expressing ﬁbrovascular tissue and inﬁltra-
tion of inﬂammatory cells into the marrow spaces, with increased
endothelial cell proliferation and vascular density23. The increased
number of blood vessels is accompanied by extensions of sympa-
thetic and sensory nerves from the subchondral bone to occupy the
osteochondral channels and invade the normal cartilage to increase
nerve growth factor expression within vascular channels24. Animal
models have shown increased angiogenic activity of subchondral
bone in the early to progressive stages of OA, followed by vascular
invasion into the osteochondral junction25,26.
Crosstalk in boneecartilage interface
Studies using sodium ﬂuorescein27 have demonstrated in vivo
that a number of molecules can diffuse through the boneecartilage
interface. Variations in the degree of mineralisation, together with
the microcracks and ﬁssures that occur in OA, likely further facili-
tate this transport and cellular crosstalk. Hwang et al.28 reported
that the hydraulic conductance of the articular cartilage and sub-
chondral bone plate increases with OA progression. These ﬁndings
are linked to the increased density of enlarged subchondral canals
penetrating the calciﬁed cartilage in samples with partially eroded
cartilage.
During the progression of OA, an increasing number of large
transport conduits (vascular channels or marrowcavities) break the
osteochondral interface and increase signiﬁcantly the overall
transport capacity across the joint, overcoming the barrier posed by
the denser ECM. Pan et al. found using a photobleaching (FLIP)
method that sodium ﬂuorescein diffuses across the calciﬁed carti-
lage and osteochondral interface at a much higher rate in two
murine models of OA than in normal joints; both cartilage damage
and vascular invasion can increase crosstalk via diffusion of small
molecules29. Bone turnover also leads to elevated crosstalk be-
tween cartilage and subchondral bone during OA. A study using OA
X.L. Yuan et al. / Osteoarthritis and Cartilage 22 (2014) 1077e10891080mouse models showed early and temporal subchondral plate
porosity and increased perforation in OA with enhanced
biochemical and mechanical interactions among the subchondral
trabeculae, bone marrow cells and articular cartilage30.Cellular interactions in crosstalk in vitro
Crosstalk in molecular interactions between chondrocytes and
osteoblasts, osteoclasts and osteocytes has been investigated using
a number of in vitro systems. These cellular interaction experi-
ments (Table I) suggest potential mechanisms of action in an
artiﬁcial environment and could provide a basis for further in vivo
models. Sanchez et al. showed that subchondral bone osteoblasts
from OA patients exhibit increased production of bone anabolic
molecules and altered phenotypes31. Furthermore, Westacott et al.
suggested that various cytokines and growth factors secreted by
subchondral bone cells of OA patients promote loss of cartilage
proteoglycans32.
Local factors secreted by osteoblasts also contribute to cartilage
degradation. Osteoblasts derived from osteoarthritic sclerotic bone
with osteoarthritic articular chondrocytes exhibit decreased pro-
duction of aggrecan and chondrocyte markers (SOX9 and COL2),
but increased production of MMP3 and MMP13, suggesting that
local factors secreted by osteoblasts initiate chondrocyte hyper-
trophy and matrix mineralisation33,34.
Recently, possible crosstalk between osteoclasts or macro-
phages and chondrocytes has been reported. Co-culture of human
articular chondrocytes and macrophages has revealed crosstalk
involving MMP-1, MMP-3 and MMP-935. MMP-9 in co-culture
medium originated from macrophages and its activation required
not only chondrocyte-derived factors but also the presence of
MMP-3 and MMP-1; however, the mechanism involved remains
unclear. Additionally, similar crosstalk occurs between osteoblasts
and osteocytes. Extracellular matrix produced by OA subchondral
bone osteoblasts results in downregulation of integrin b1 expres-
sion and upregulation of MMP2 and MMP9 expression, suggesting
that osteoblasts may lead to abnormal osteocyte phenotypic
changes36.In vivo molecular interactions in crosstalk processes (Fig. 3)
Molecular interactions in the boneecartilage interface provide
insight into the speciﬁc mechanisms underlying the effects of
crucial biological factors and signalling pathways on cartilage-bone
pathophysiology in OA (Table I). Factors released from subchondral
bone tissue may induce OA cartilage degradation. Conversely,
subchondral bone remodelling may be a result of factors secreted
from cartilage. An imbalance of molecular interactions may also
lead to cartilage damage and subchondral bone remodelling,
contributing to abnormal crosstalk37.Table I
The main methods used for the inclusion of studies on crosstalk
Crosstalk Methods
Cellular interaction Cell Co-culture
Molecular interaction Photobleaching (FLIP)
Perfusion testing
Inhibition of speciﬁc factors or signalling pathways
Activation of speciﬁc factors or signalling pathways
Antagonists and agonists of signalling pathways
Knockout of speciﬁc genes
Transgenic technologyBiological factors
Osteoprotegerin (OPG), receptor activator of nuclear factor-kB
(RANK) and RANK ligand (RANKL)
The molecular triad of OPG, RANK and RANKL is a key cytokine
system involved in the regulation of bone resorption38. In the bone
remodelling process, RANKL, expressed by osteoblastic lineage cells
as well as chondrocytes, is essential for mediating bone resorption
through osteoclastogenesis and activating mature osteoclasts by
binding to RANK, which is present on precursor and mature oste-
oclasts and expressed only by chondrocytes. OPG is produced by
osteoblasts/stromal cells and inhibits the binding of RANKL to
RANK39,40.
The RANKL to OPG ratio was reported to be increased in human
OA cartilage comparedwith normal cartilage, as well as in rabbit OA
subchondral bone12,38. In recent research involving human sub-
jects, this ratio was increased in early-stage OA but decreased in
late-stage OA41. Inhibition of RANKL by systemic42 or intra-artic-
ular43 administration of OPG in mice prevented bone and cartilage
degradation, and treatment with a modiﬁed OPG (OPG-Fc) atten-
uated the OA changes and reduced pain behaviour in rats44.
Hepatocyte growth factor (HGF)
Another molecular interaction across the boneecartilage inter-
face involves HGF, which is localised in osteoarthritic calciﬁed
cartilage and the deep zone of mild osteoarthritic cartilage. HGF can
promote synthesis of type II collagen and proteoglycan as well as
collagenase-3 and MMP3 production45. However, research on hu-
man OA showed that HGF is synthesised by osteoarthritic osteo-
blasts from the subchondral bone plate and diffuses to the cartilage
region, suggesting that subchondral bone osteoblasts are respon-
sible for the HGF present in OA cartilage46. In addition, HGF is a
potent inhibitor of bone resorption but increases osteoblastic
function47, which may induce a positive bone remodelling balance
by both decreasing bone resorption and increasing bone formation.
Hypoxia-inducible factor-2a (HIF-2a)
HIF-2a, which is encoded by Epas1, is expressedmainly in highly
differentiated chondrocytes and is a major catabolic transcription
factor in the OA process. Another possible example of crosstalk at
the boneecartilage interface is based on the increased HIF-2a
expression in osteoarthritic cartilage, which can lead to cartilage
breakdown and endochondral bone formation48.
Yang et al. ﬁrst showed that HIF-2a causes progressive cartilage
damage by upregulating directly the expression of a set of matrix-
degradative enzymes. Moreover, mice transgenic for Epas1 only in
chondrocytes showed spontaneous cartilage destruction, whereas
heterozygous genetic deletion of Epas1 suppressed cartilage
destruction with concomitant reductions in catabolic factor
levels49. Furthermore, increased HIF-2a levels in OA chondrocytes
were associated with increased apoptosis of articular chondrocytes,Observation index Typical Reference
Various cytokines, growth factors secreted by osteoblast,
osteoclast and chondrocyte
Sanchez et al.33
The diffusivity of sodium ﬂuorescein Pan et al.29
Hydraulic conductance Hwang et al.28
IGF, TGF-b, b-catenin Zhu et al.61
Wnt Zhu et al.62
WISP-1, Wnt 16, Wnt2B Blom et al.66
Wnt/b-catenin, Epas1 Ryu et al.50
Epas1 Yang et al.49
Fig. 3. Molecular and cellular crosstalk at the osteochondral junction in OA. The presence of connections (microfractures, ﬁssures, vascular channels and blood vessels) between
subchondral bone and cartilage contributes to elevated crosstalk between chondrocytes, osteoblasts and osteoclasts through biological factors and signalling pathways. Subchondral
bone is exposed to factors produced by hypertrophic chondrocytes, such as MMPs and ADAMTs. Reciprocally, invasion of the articular cartilage by vascular channels exposes
chondrocytes to cytokines and growth factors from subchondral tissues, such as VEGF, NGF, IL-1, IL-6, HGF, or IGF-1. The imbalance of OPG/RANKL has multiple effects on bone and
cartilage. HIF-2a is associated with advancing endochondral ossiﬁcation and chondrocyte hypertrophy. TGF-b1 and The Wnt/b-catenin signalling pathways have emerged as key
regulators of bone and cartilage. The effects of speciﬁc Wnt agonists and antagonistsdincluding sFRP-3 and DKK1-2don these tissues remain to be elucidated.
X.L. Yuan et al. / Osteoarthritis and Cartilage 22 (2014) 1077e1089 1081enhanced Fas expression and cartilage destruction. Chondrocyte-
speciﬁc knockout of Epas1 and Fas deﬁciency in mice suppressed
chondrocyte apoptosis and inhibited OA cartilage destruction50.
Moreover, elevated HIF-2a may contribute to endochondral
ossiﬁcation in OA51. HIF-2a is essential for chondrocyte hypertro-
phic differentiation, followed by cartilage matrix degradation and
vascular invasion, and enhances the promoter activities of many
key factors, including COL10A1, MMP13, VEGFA, RUNX2 and Indian
hedgehog (IHH). The signals that induce endochondral ossiﬁcation
cause cartilage degradation at the centre of the joint and osteo-
phyte formation at the periphery52.
HIF-2a expression is related to OA development; expression is
induced and peaks in early-stage OA but is downregulated in late-
stage OA. HIF-2a may suppress chondrocyte autophagy and coun-
teract HIF-1a activity53. Consequently, the control of cartilage
homeostasis may be related to the balance between HIF-1a and
HIF-2a activities because HIF-1a functions to maintain cartilage
while HIF-2a induces endochondral ossiﬁcation and cartilage
degradation. The shift from HIF-1a to HIF-2a expression might be a
pathogenetic feature of OA and has been considered a potential
target for a novel therapeutic strategy54.
Boneecartilage modulatory pathway
Transforming growth factor b (TGF-b)
TGF-b signalling is required for maintenance of the metabolic
homeostasis and structural integrity of healthy cartilage. TGF-b is
highly expressed in normal cartilage but almost absent inosteoarthritic cartilage. Loss or interruption of TGF-b signalling in
cartilage results in loss of proteoglycans and cartilage degenera-
tion55. Inhibition of endogenous TGF-b leads to increased damage
to cartilage56 and prevents osteophyte formation and synovial
ﬁbrosis57.
The effect of TGF-b signalling on cartilage includes promotion of
homeostasis through the classical Smad2/3 pathway via actin ALK5
and induction of chondrocyte hypertrophy through the Smad1/5/8
pathway viaALK158. Increased production of TGF-b by deteriorating
cartilage under osteoarthritic conditions together with an elevated
ALK1 to ALK5 ratio might affect homeostasis of both the cartilage
and bone in joints, indicating an intermediate crosstalk between
cartilage and bone. Zhen et al. showed that TGF-b is activated in
subchondral bone in response to altered mechanical loading in an
ACLT mouse model of OA59. Increased TGF-b levels in subchondral
bone increase the numbers of mesenchymal stem cells (MSCs),
osteoprogenitors and osteoblasts, leading to aberrant bone
remodelling and angiogenesis. Whether MSC-speciﬁc genetic
ablation of TGF-b receptor II (Tgfbr2) or antibody-mediated neu-
tralisation of TGF-b in subchondral bone can reduce osteoarthritic
damage and improve bone parameters, cartilage structure and joint
functionality, remains unclear.
Wnt/b-catenin pathway
Studies have shown that the Wnt/b-catenin signalling pathway
plays a critical modulatory role in maintaining the bone-cartilage
biochemical unit. The biochemical effects of activated Wnt signal-
ling contribute to excessive bone remodelling and degradation of
Table II
Summary of main clinical studies using inhibiting crosstalk agents for OA treatment
Category Therapeutic agents Study design Case Time Treatment dose/procedure OA location Outcomes Study authors
Anti-NGF Tanezumab Proof-of-concept study, 365 6 m 10,25,50,100,200 mg/kg on day 1 and 56
IV
Knee Improveme in WOMAC score, knee
pain and PG measure
Lane et al.(2010)70
Phase II, multicenter, open-label,
multiple-dose extension of an earlier
randomized trial
239 56 w 50 mg/kg on Days 1 and 56 with
subsequent doses administered at 8-
week intervals IV
Knee Modiﬁed W AC physical function
score and S with a low incidence of
AEs
Schnitzer et al.(2011)71
NCT00399490
Randomized, double-blind, placebo-
controlled, dose-escalation, single
intravenous (IV) dose, two-part study
67 13 w/17 w Part I:10,25,50,100,200 mg/kg
Part II: 10,25,50,100 mg/kg IV
Knee Improved i x knee pain andWOMAC
pain, physi function, stiffness
subscales
Nagashima et al. (2011)
NCT00669409
Randomized, double-blind, placebo-
controlled phase III trial
518 32 w 2.5,5,10 mg IV Knee signiﬁcant rovement in WOMAC
Pain, Physi Function subscale and
PGA score
Brown et al.(2012)72
NCT00733902
Phase III, placebo- and active-controlled
study
311 18 W 5,10 mg in 8 w intervals IV Hip/Knee Improved W MAC pain, physical
function, st ess subscales and PGA
Spierings et al.(2013)75
Phase III, randomized, double-blind,
placebo-controlled, parallel-group,
multicentre trial
352 32 w 2.5,5,10 mg at weeks 0, 8 and 16 IV
combined with diclofenac 75 mg bid
Hip/Knee Improved W MAC Pain, Physical
Function su cale and PGA score;
Higher inci ce of AEs and no new
safety signa emerge
Balanescu et al.(2013)73
NCT00864097
Randomized, double-blind, placebo-
controlled, phase III trial
466 32 W 2.5,5,10 mg at weeks 0, 8 and 16 IV Hip Modiﬁed W AC pain, physical
function sc and PGA
Brown et al.(2013)74
NCT00744471
Fulranumab Randomized, double-blind, placebo-
controlled, and dose-ranging study
390 26 w 1,3 mg Q4wk; 3,8,10 Q8wk IH Hip/Knee Positive eff on OAPI,WOMAC
subscales a score, BPI-SF subscales
and PGA sc ; well tolerated
Sanga et al.(2013)76
NCT00973141
Bisphosphonates Alendronate CS 57 36 m Knee Modiﬁed W AC pain scale, MRI
ﬁndings
Carbone et al.(2004)90
Prospective randomized caseecontrol
study
33 24 m 35 mg/week PO Hip Improved V andWOMAC pain scores,
Decreased nary NTX-I,CTX-II, No
improveme of radiograph
progression
Nishi et al.(2012)91
Risedronate Prospective, double-blind, placebo-
controlled study (BRISK study)
151 12 m 5 mg/d or 15 mg/d PO Knee Improved j t space narrowing of X-
ray, WOMA ndex and PGA scores
Spector et al.(2005)86
Two parallel phase III Prospective,
double-blind, multi-centre, placebo-
controlled study
1861 24 m 5 mg/d,15 mg/d,35 mg/wk(EU) PO
5 mg/d,15 mg/d,50 mg/wk(NA) PO
Knee No improv ent of WOMAC, PGA
scores and iograph progression,
Decreased nary NTX-I,CTX-II
Bingham et al.(2006)88
Garnero et al.(2008)89
Double blind, multi-centre, placebo-
controlled study (KOSTAR study)
929 24 m 5 mg/d,15 mg/d,50 mg/wk PO Knee Modiﬁed X y and FSA Buckland-Wright et al.(2007)87
Randomized non-blinded caseecontrol
study
33 18 m 2.5 mg/d PO Knee No sympto tic beneﬁt Kawasaki et al.(2008)
Clodronate PhaseⅡ randomized partially blind
clinical trial
117 1 m 0.5/1/2 mg
1 IA/week for 4 weeks, 1 mg 2 IA/
week for 2 weeks
Knee Improved V scores, Lequesne index,
Joint exten n and mobility scores
Rossini et al. (2009)92
Zoledronic acid Randomized double-blind placebo-
controlled trial
31 12 m 5 mg/100 ml IV Knee Decreased scores and BML area, No
improveme in KOOS scale
Laslett et al. (2012)93
ACTRN 12609000399291
Calcitonin Salmon calcitonin Phase II Randomized double blind,
placebo-controlled trial
152 3 m 0.15 mg/d,0.4 mg/d,1 mg/d,2.5 mg/d PO Knee Decreased nary CTX-I,CTX-II Bagger et al.(2005)100
Randomized, double-blind trial 35 3 m 0.5 mg/d,1 mg/d PO Knee Improved L uesne's algofunctional
index score ecreased urinary and
serum leve f CTX-II, C2C and MMP13
Manicourt et al.(2006)101
Phase I randomized, double-blind,
double-dummy, placebo-controlled,
gender-stratiﬁed study
50 2 w 0.6 mg/bid,0.8 mg/bid PO Knee Reduced se CTX-I and urinary CTX-
II
Karsdal et al.(2010)102
NCT00486369
Self-control study 220 12 m 200 IU/d Nasal spray form Knee Improved V and WOMAC scores Esenyel et al.(2012)104
Randomized caseecontrol study 30 6 m 200 IU/d nasal spray form Knee Improved V and WOMAC scores,
Decreased um NO and urinary CTX-II
Armagan et al.(2012)103
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result in cartilage damage, OA-like lesions and chondrocyte
apoptosis, perturb the articular chondrocyte phenotype, and
upregulate markers associated with hypertrophy and terminal
differentiation61,62. Conversely, overexpression of Wnt signalling is
deleterious to chondrocytes, leading to OA-like disease. Frizzled-
related protein 3 (FRP3) is a Wnt antagonist. FRP-knockout mice
are more susceptible to cartilage damage in OA and show MMP
activation and loss of proteoglycans63. Besides chondrogenesis,
Wnt signalling is essential for bone remodelling. Activation of Wnt
signalling, either through knockdown of Wnt antagonists or by
overexpression of b-catenin, resulted in increased bone formation
in mice, leading to thicker and stiffer bones62,63.
Various antagonists and agonists of the Wnt/b-catenin pathway
including sclerostin (SOST), secreted frizzled-related protein (sFRP)
and Dickkopf (DKK1) may be crosstalk effector molecules that
function to maintain normal homeostasis. sFRP-3 might protect
against the progression of cartilage loss in OA. An elevated serum
Dkk-1 level is associated with reduced progression of hip OA64. Two
rat models of OA treated with antisense oligonucleotide DKK1
showed less cartilage damage and reduced bone remodelling65.
Moreover, increased expression of Wnt signalling agonists, such as
Wnt-induced signalling protein 1 (WISP-1), Wnt16 and Wnt-2B,
were reported in human OA cartilage and may contribute to carti-
lage degradation by upregulating MMPs and aggreganases66.
Another example ofWnt/b-catenin pathway crosstalk with TGF-
b signalling has been reported recently. The secretion of WISP-1
may have an osteogenic effect on the underlying subchondral
bone by enhancing osteoblast differentiation. Additionally, WISP-1
can modulate TGF-b signalling by inhibiting Smad267. The inter-
action between TGF-b and WNT pathways mediated by WISP-1
may play a critical role during OA progression at the bone-
ecartilage interface.
Therapeutic strategies based on crosstalk (Table II)
Targets of angiogenesis and neurogenesis: channel closing
Targeting and inhibiting angiogenesis and neurogenesis to
decrease the molecular interaction and maintain the integrity of
the osteochondral junction may therefore identify new therapeutic
strategies for treating OA and yield direct symptomatic beneﬁts68.
Strategies include direct inhibition by agents that act on VEGF and
b-NGF, or indirect inhibition of the matrix degradation and osteo-
chondral channel formation necessary for the growth of blood
vessels. The angiogenesis inhibitor PPI-2458 reduced the number of
vascularised channels and joint damage while simultaneously
reducing pain behaviour in an OA animal model26. Because the
neovascularisation mechanisms are similar in tumours and osteo-
arthritic joints, the VEGF-blocking antibodies bevacizumab, rani-
bizumab and ramucirumab may prove beneﬁcial for the treatment
of OA. Intravenous administration of bevacizumab can enhance
articular cartilage repair in an osteochondral defect model69.
Dual inhibition of angiogenesis and nerve growth could be an
attractive therapeutic strategy for patients with OA. The humanised
monoclonal anti-NGF antibody tanezumab blocks NGF binding to
its receptors, thereby improving function and reducing joint pain in
patients with knee OA70. In a phase II clinical trial by Schnitzer
et al.71, long-term repeated injections of tanezumab in patients
with moderate-to-severe knee OA provided continued pain relief
and improved function with a low incidence of side effects. More-
over, tanezumab is well tolerated and effective for analgesic treat-
ment of knee OA72. A 32-week follow-up clinical trial of sustained-
release tanezumab combined with diclofenac in patients with knee
or hip OA showed a higher incidence of adverse events (AEs), which
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vestigations of tanezumab monotherapy are required73. In recent
phase III studies, Brown et al. analysed 466 patients with osteoar-
thritic hips given three intravenous tanezumab injections at
8-week intervals. Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) pain and physical function subscale
scores demonstrated statistically signiﬁcant improvements as
compared with baseline or placebo74. Similar results were reported
by another phase III clinical trial in osteoarthritic hip or knee pa-
tients75. Sanga et al. found that subcutaneous injections of the new
human monoclonal anti-NGF antibody fulranumab resulted in
signiﬁcant pain reduction and improved physical function and was
generally well tolerated76.
Targets of subchondral bone remodelling: structural repair
Osteochondral structure provides ample pathways, including
vascular tunnels, ﬁssures and cracks, for intimate molecular
crosstalk. The accelerated remodelling process in osteoarthritic
subchondral bone may cause osteoclastic resorption and increased
porosity in subchondral regions, leading to elevated crosstalk be-
tween bone and cartilage. Based on the results demonstrating a
remodelling process in the subchondral bone during OA, whether
factors capable of inﬂuencing bone remodelling could be used as
therapeutic strategies remains questionable. Various antiresorptive
agents appear well suited to preventing the progression of OA as
modulators of subchondral bone remodelling.
Bisphosphonates (BPs)
Various BPs (alendronate, risedronate, tiludronate and zole-
dronic acid) decrease vascular invasion of calciﬁed cartilage, inhibit
subchondral bone remodelling, reduce subchondral bone loss and
inhibit osteophyte formation77,78. These agents also modulate the
OPG/RANKL system, inhibit osteoclast activity and reduce pain
behaviour79,80. In the rat ACL transection model, Hayami et al.
demonstrated dose-dependent chondroprotective effects of
alendronate in terms of osteophyte formation inhibition and re-
ductions in the levels of cartilage degradation biomarkers78. Other
studies have conﬁrmed the beneﬁcial chondroprotective effects
and bone remodelling of alendronate and pamidronate in experi-
mental OA models81,82. However, different results were reported
from use of the spontaneous guinea pig model, in which alendro-
nate increased the bone density and mineral content and was
associated with aggravated cartilage degradation83. Additionally,
the treatment timepoint is crucial for the effectiveness of BPs. Zhu
et al.84 showed that early treatment of OVX rats with alendronate
signiﬁcantly attenuated cartilage erosion by inhibiting subchondral
bone loss. Pre-emptive alendronate treatment prevented increased
bone turnover, reduced cartilage degradation and preserved the
structural integrity of subchondral bone in low-dose monosodium
iodoacetate (MIA)-induced knee OA in rats85.
Treatment with BPs has shown no deﬁnite disease-modifying
effect in humans; however, several studies revealed a potential
beneﬁt of risedronate and alendronate in OA in terms of inhibiting
subchondral bone remodelling and improving symptoms and
progression of the disease at various locations. Risedronate has
been evaluated in phase II and phase III clinical trials, showing
positive effects on OA in phase II and negative effects in phase III
trials86e88. In a 1-year prospective, double-blind, placebo-
controlled study of knee OA, Spector et al. reported that daily
treatment with 15-mg risedronate improved the WOMAC index
and patient global assessment (PGA) scores as well as signiﬁcantly
decreased levels of markers of cartilage degradation and bone
resorption86. Risedronate has also been shown to maintain or in-
crease vertical trabeculae number, thereby preserving thestructural integrity of subchondral bone in a 2-year longitudinal
radiographic study of knee OA87. However, the effects of risedronate
on the symptoms of knee OA were inconsistent. In a phase III par-
allel trial, risedronate failed to showany disease-modifying effect in
patients, even though the levels of C-terminal crosslinking telo-
peptide of type II collagen (CTX-II), a marker of cartilage degrada-
tion, were reduced88,89.
In a cross-sectional study (CS), Carbon et al. reported that
alendronate decreased the prevalence of knee OA-related sub-
chondral bone lesions and bone marrow oedema90. A 2-year
follow-up study of alendronate treatment in hip OA showed
improved WOMAC pain scores and visual analogue score (VAS)
with decreased levels of the NTX-I and CTX-II markers and no
improvement in joint space narrowing by X-ray91. Use of a sufﬁ-
cient dosage is important to assess the efﬁcacy of BPs in OA, which
might be applicable in alternative approaches. Intra-articular
clodronate provided symptomatic and functional improvements
including, higher VAS and Lequesne index score92. A study of the
effect of zoledronic acid in osteoarthritic knees suggested that
intravenous zoledronic acid (5 mg) reduced knee pain and BML size
over a 6-month period93. Finally, BPs may be useful in the early
stages of OA due to high subchondral bone remodelling observed in
clinical trials; the BP doses used must be sufﬁcient to prevent
osteochondral osteoclast activity.
Calcitonin
Salmon calcitonin (sCT) is approved for the treatment of oste-
oporosis and other diseases involving accelerated bone turnover by
reducing osteoclastic resorption directly94. Oral sCT treatment
counteracted the loss of cartilage thickness and reduced sub-
chondral bone damage and type II collagen degradation in a com-
bined meniscectomy with ovariectomy in OA rat models95. Behets
et al. reported the chondroprotective effect of sCT in a canine ACLT
OAmodel. sCT administered intranasally reduced both subchondral
bone remodelling and cartilage lesions in the early stages of OA96.
Other studies reported beneﬁcial effects following prophylactic and
therapeutic intramuscular administration of sCT in cartilage lesions
and bone turnover in the surgically induced OA rabbit model97. In a
canine ACLT OA model98, subcutaneous injections of calcitonin
under therapeutic conditions also reduced the progression of
osteoarthritic cartilage and subchondral bone changes as well as
the levels of serummarkers of bone resorption. Recently, Ryan et al.
reported that an intra-articular sCT-based nanocomplex showed
signiﬁcant anti-inﬂammatory effects by reducing the mRNA levels
of the inﬂammation marker NR4A299.
In clinical trials, Manicourt and Bagger et al. reported oral sCT
signiﬁcantly decreased joint pain and function scores as well as
levels of bone and cartilage degradation biomarkers100,101. Similar
results were reported in recent studies. Karsdal and colleagues
reported the positive effects of a novel sCT oral formulation deliv-
ered with 5-CNAC on bone resorption and cartilage degradation in
terms of the reduction in the levels of the CTX-I and CTX-II102.
Additionally, nasal sCT treatment in knee OA showed positive
chondroprotective effects based on improved WOMAC index, VAS
and serum NO103. A 1-year follow-up clinical trial of nasal sCT
treatment showed similar results and exhibited dual effects on
osteoporosis and knee OAwith signiﬁcant improvements in quality
of life104. Additional in-depth phase III clinical trials and subsequent
analyses are needed to investigate the potential positive effects of
calcitonin on the pathogenesis of OA.
Strontium ranelate
Strontium ranelate (Sra) is an agent with dual effects on bone
metabolism in postmenopausal osteoporosis based on the coupling
of decreased bone resorption and increased bone formation105. A
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fects in OA. Sra increased human cartilage matrix formation
in vitro106. This drug also stimulated OPG and inhibited RANKL
synthesis in human OA subchondral bone osteoblasts, and reduced
MMP2 and MMP9 expression107. Pelletier et al. demonstrated that
Sra reduced subchondral bone thickening and articular cartilage
lesions by inhibiting key metalloproteases and IL-1b in a canine
ACLT OA model108.
Recently, several studies have explored the clinical efﬁcacy of
Sra in OA. In a post hoc trial in females with osteoporosis and
concomitant spinal OA, oral Sra reduced both the progression of
radiographic features and back pain109. Alexandersen et al. re-
ported that Sra reduced the urinary levels of the cartilage turnover
marker CTX-II110. Additionally, Reginster et al. demonstrated that
Sra (2 g/day) provided a beneﬁcial effect on radiographic pro-
gression based on joint space narrowing and greater reductions in
WOMAC score and the pain subscore in a large, 3-year, randomised
clinical trial111.Anti-cathepsin K
Cathepsin K is the main osteolytic cysteine protease secreted by
osteoclasts, and it plays a critical role in the degradation of the bone
matrix and type I collagen112. Cathepsin K inhibitors have been
suggested to prevent both bone loss and cartilage degeneration.
Two novel cathepsin K inhibitors were shown to hinder the pro-
gression of OA and reduce joint pain in a canine partial medial MNX
OA model and a guinea pig spontaneous OA model113,114. Recently,
Hayami et al. reported that inhibition of cathepsin K prevented
ACLT-induced OA in rabbits and mice, showing beneﬁcial effects on
subchondral bone, cartilage and osteophytes115. This result was in
contrast to a study employing the human tumour necrosis fac-
toretransgenic mouse model in cathepsin K-deﬁcient mice, in
which a partial protective role in arthritic bone destruction was
identiﬁed116.Bone-forming agents: parathyroid hormone (PTH)
A number of in vitro and in vivo studies have indicated that PTH,
known as teriparatide in drug form, inﬂuences articular cartilage
homeostasis and may be chondroprotective. PTH[1-34] inhibited
expression of COL10 and stimulated expression of COL2 in MSCs
from OA patients117. Sampson et al. reported that teriparatide pro-
tected against cartilage degeneration and induced matrix regen-
eration in a mouse model of injury-induced OA118. Chang et al.
demonstrated that intermittent injection of PTH[1-34] inhibited
terminal differentiation of human articular chondrocytes in vitro
and reduced OA progression in rats119. Additionally, they developed
PTH/PLGA microspheres, which cause sustained release of PTH,
resulting in suppression of OA progression in a papain-induced OA
rat model120. Chondrodestructive effects upon exposure of articular
cartilage to PTH have been reported. Brennan et al. showed that
higher levels of PTH were detrimental to cartilage and reduced its
healing properties following minor injury in humans in vivo121.
Recently, PTH-induced alterations of normal subchondral bone
microarchitecture were investigated, and found to result in carti-
lage damage and provoke early osteoarthritic changes122. Bellido
et al.123 demonstrated that the improvements in themicrostructure
and integrity of subchondral bone due to PTH[1-34] may prevent
cartilage damage progression in rabbits with early OA preceded by
osteoporosis, underlining the intimate crosstalk between articular
cartilage and subchondral bone. Intermittent PTH[1-34] adminis-
tration also ameliorated synovial changes associated with cartilage
damage124. Although further research is warranted, studies of
bone-forming agents can provide novel targets in subchondral
bone remodelling for the treatment of OA.Conclusion and perspectives
The boneecartilage interface is a biocomposite functional unit
that has attracted interest for its uniquely synergistic and cooper-
ative function in OA. Due to the close physical association between
cartilage and subchondral bone many physical and functional al-
terations can occur through molecular interaction across the
interface. Elevated molecular transport was identiﬁed in osteoar-
thritic joints based on osteochondral angiogenesis and bone
remodelling. The presence of vascular invasion from subchondral
bone into the cartilage zone and the existence of microcracks and
ﬁssures, and subchondral bone remodelling, provide pathways of
communication across the osteochondral interface.
Recent studies in vitro and in vivo have shown that crosstalk
affects cartilage and subchondral bone in synovial joints. Several
critical biological factors and signalling pathways, including HIF-2a,
OPG/RANK/RANKL, TGF-b and Wntb-catenin, in both tissues may
play regulatory roles in OA progression and the homeostasis of
neighbouring tissues. The role of the crosstalk at the bone-
ecartilage interface in the progression of OA requires additional
evidence at the molecular level using genomics, epigenetics, pro-
teomics and metabolomics approaches. An increasing number of
potentially effective target candidates for OA therapy, including
agonists or inhibitors of molecules and knockout of speciﬁc genes,
may lead to breakthroughs in OA research and therapy.
Increased understanding of crosstalk between the cartilage and
bone in joints during OA will result in new treatments that inhibit
or protect the involved pathways. Targeting angiogenesis, neuro-
genesis and subchondral bone remodelling to decrease the mo-
lecular interaction may help to identify novel therapeutic strategies
for treatment of OA. Several approaches, such as liposome and
nanoparticle systems for local intra-articular delivery of agents,
to the treatment of OA are under development. In conclusion,
extensive cellular and molecular studies of crosstalk at the bone-
ecartilage interface will aid our understanding the pathophysi-
ology of OA and improve existing therapeutic strategies. Advances
in research and technology are facilitating the development of
novel drugs and agents that speciﬁcally block mechanisms of
crosstalk responsible for the structural changes in osteoarthritic
joint tissue, and should be evaluated in clinical trials.
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